Effects of lithium and valproic acid on BDNF protein and gene expression in an in vitro human neuron-like model of degeneration

Journal of Psychopharmacology

Volumn 28, Issue 10, 2014, Pages 964-972

  Croce, Nicoletta ^a,b   Mathé, Aleksander A ^c   Gelfo, Francesca ^a,b   Caltagirone, Carlo ^a,b   Bernardini, Sergio ^b   Angelucci, Francesco ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

BDNF; Excitotoxicity; L glutamate; Lithium; Neuronal survival; SH SY5Y; Valproic acid

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; LITHIUM CARBONATE; NEUROPROTECTIVE AGENT; VALPROIC ACID;

BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NERVE CELL; TUMOR CELL LINE;

BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; GENE EXPRESSION REGULATION; GLUTAMIC ACID; HUMANS; LITHIUM CARBONATE; NEURONS; NEUROPROTECTIVE AGENTS; VALPROIC ACID;

EID: 84901806913     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114529379     Document Type: Article

References (93)

1. Angelucci F, Aloe L, Jiménez-Vasquez P and Mathé AA (2003) Lithium treatment alters brain concentrations of nerve growth factor, brainderived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol 6:225-231.
2. Arancio O and Chao MV (2007) Neurotrophins, synaptic plasticity and dementia. Curr Opin Neurobiol 17:325-330.
3. Asai T, Bundo M, Sugawara H, et al. (2013) Effect of mood stabilizers on DNA methylation in human neuroblastoma cells. Int J Neuropsychopharmacol 16:2285-2294.
4. Bachmann RF, Schloesser RJ, Gould TD and Manji HK (2005) Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 32:173-202.
5. Balaratnasingam S and Janca A (2012) Brain derived neurotrophic factor: a novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol Ther 134:116-124.
6. Baquet ZC, Bickford PC and Jones KR (2005) Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 25:6251-6259.
7. Bezchlibnyk YB, Sun X, Wang JF, MacQueen GM, McEwen BS and Young LT (2007) Neuron somal size is decreased in the lateral amygdalar nucleus of subjects with bipolar disorder. J Psychiatry Neurosci 32:203-210.
8. Carvalho AL, Caldeira MV, Santos SD and Duarte CB (2008) Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol 153:S310-S324.
9. Castro AA, Ghisoni K, Latini A, Quevedo J, Tasca CI and Prediger RD (2012) Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. Behav Brain Res 229:208-215.
10. Cechinel-Recco K, Valvassori SS, Varela RB, et al. (2012) Lithium and tamoxifen modulate cellular plasticity cascades in animal model of mania. J Psychopharmacol 26:1594-1604.
11. Chang K, Barnea-Goraly N, Karchemskiy A, et al. (2005) Cortical magnetic resonance imaging findings in familial pediatric bipolar disorder. Biol Psychiatry 58:197-203.
12. Chiu CT, Liu G, Leeds P and Chuang DM (2011) Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 36:2406-2421.
13. Chiu CT, Wang Z, Hunsberger JG and Chuang DM (2013) Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 65:105-142.
14. Chuang DM (2004) Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 16:83-90.
15. Chuang DM and Manji HK (2007) In search of the holy grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry 62:4-6.
16. Cohen-Cory S, Kidane AH, Shirkey NJ and Marshak S (2010) Brainderived neurotrophic factor and the development of structural neuronal connectivity. Dev Neurobiol 70:271-288.
17. Cousins DA and Grunze H (2012) Interpreting magnetic resonance imaging findings in bipolar disorder. CNS Neurosci Ther 18:201-207.
18. Croce N, Dinallo V, Ricci V, et al. (2011) Neuroprotective effect of neuropeptide Y against β-amyloid 25-35 toxicity in SH-SY5Y neuroblastoma cells is associated with increased neurotrophin production. Neurodegener Dis 8:300-309.
19. Cunha AB, Frey BN, Andreazza AC, et al. (2006) Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 398:215-219.
20. De Sousa RT, Van De Bilt MT, Diniz BS, et al. (2011) Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett 494:54-56.
21. Dias VV, Brissos S, Frey BN, Andreazza AC, Cardoso C and Kapczinski F (2009) Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord 11:663-671.
22. Drevets WC (2001) Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11:240-249.
23. Einat H, Yuan P, Gould TD, et al. (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23:7311-7316.
24. Ekman CJ, Lind J, Ryden E, Ingvar M and Landen M (2010) Manic episodes are associated with grey matter volume reduction - a voxelbased morphometry brain analysis. Acta Psychiatr Scand 122:507-515.
25. Enciu AM, Nicolescu MI, Manole CG, Muresanu DF, Popescu LM and Popescu BO (2011) Neuroregeneration in neurodegenerative disorders. BMC Neurol 11:75.
26. Femenía T, Gómez-Galán M, Lindskog M and Magara S (2012) Dysfunctional hippocampal activity affects emotion and cognition in mood disorders. Brain Res 1476:58-70.
27. Feng HL, Leng Y, Ma CH, Zhang J, Ren M and Chuang DM (2008) Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 155:567-572.
28. Fischer A, Sananbenesi F, Wang X, Dobbin M and Tsai LH (2007) Recovery of learning and memory is associated with chromatin remodelling. Nature 447:178-182.
29. Forlenza OV, De Paula VJ, Machado-Vieira R, Diniz BS and Gattaz WF (2012) Does lithium prevent Alzheimer's disease? Drugs Aging 29:335-342.
30. Frey BN, Andreazza AC, Ceresér KM, et al. (2006) Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 79:281-286.
31. Frey BN, Zunta-Soares GB, Caetano SC, et al. (2008) Illness duration and total brain gray matter in bipolar disorder: evidence for neurodegeneration? Eur Neuropsychopharmacol 18:717-722.
32. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A and Yamawaki S (2001) Chronic lithium treatment increases the expression of brainderived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 158:100-106.
33. Giménez-Cassina A, Lim F and Díaz-Nido J (2012) Chronic inhibition of glycogen synthase kinase-3 protects against rotenone-induced cell death in human neuron-like cells by increasing BDNF secretion. Neurosci Lett 531:182-187.
34. Hao Y, Creson T, Zhang L, et al. (2004) Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 24:6590-6599.
35. Hashimoto K, Shimizu E and Iyo M (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 45:104-114.
36. Hashimoto R, Hough C, Nakazawa T, Yamamoto T and Chuang DM (2002) Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 80:589-597.
37. Hennion JP, El-Masri MA, Huff MO and El-Mailakh RS (2002) Evaluation of neuroprotection by lithium and valproic acid against ouabaininduced cell damage. Bipolar Disord 4:201-206.
38. Jakobsson J, Zetterberg H, Blennow K, Johan Ekman C, Johansson AG and Landén M (2013) Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. Neuropsychopharmacology 38:664-672.
39. Jornada LK, Moretti M, Valvassori SS, et al. (2010) Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain. J Psychiatr Res 44:506-510.
40. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G and Aubry JM (2002) Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109:143-148.
41. Kempton MJ, Geddes JR, Ettinger U, Williams SC and Grasby PM (2008) Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 65:1017-1032.
42. Kida S (2012) A functional role for CREB as a positive regulator of memory formation and LTP. Exp Neurobiol 21:136-140.
43. Konarski JZ, McIntyre RS, Kennedy SH, Rafi-Tari S, Soczynska JK and Ketter TA (2008) Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord 10:1-37.
44. Lauterbach EC (2013) Neuroprotective effects of psychotropic drugs in Huntington's disease. Int J Mol Sci 14:22558-22603.
45. Lauterbach EC, Fontenelle LF and Teixeira AL (2012) The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease. Parkinsons Dis 2012;1-15.
46. Leng Y and Chuang DM (2006) Endogenous-synuclein is potently induced by valproate and participates in the neuroprotection against glutamate excitotoxicity. J Neurosci 26:7502-7512.
47. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P and Chuang DM (2008) Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 28:2576-2588.
48. Lenox RH and Wang L (2003) Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol Psychiatry 8:135-144.
49. Leyhe T, Eschweiler GW, Stransky E, et al. (2009) Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 16:649-656.
50. Lin D, Mok H and Yatham LN (2006) Polytherapy in bipolar disorder. CNS Drugs 20:29-42.
51. Lv L, Han X, Sun Y, Wang X and Dong Q (2012) Valproic acid improves locomotion in vivo after SCI and axonal growth of neurons in vitro. Exp Neurol 233:783-790.
52. Machado-Vieira R, Dietrich MO, Leke R, et al. (2007) Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 61:142-144.
53. Machado-Vieira R, Manji HK and Zarate CA (2009) The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 11:92-109.
54. Manji HK, Drevets WC and Charney DS (2001) The cellular neurobiology of depression. Nat Med 7:541-547.
55. Manji HK, Quiroz JA, Sporn J, et al. (2003) Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53:707-742.
56. Marini AM, Jiang X, Wu X, et al. (2004) Role of brain-derived neurotrophic factor and NF-kappaB in neuronal plasticity and survival: from genes to phenotype. Restor Neurol Neurosci 22:121-130.
57. Mora A, González-Polo RA, Fuentes JM, Soler G and Centeno F (1999) Different mechanisms of protection against apoptosis by valproate and Li+. Eur J Biochem 266:886-891.
58. Mössner R, Daniel S, Albert D, et al. (2000) Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int 36:197-202.
59. Murer MG, Yan Q and Raisman-Vozari R (2001) Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63:71-124.
60. Nagahara AH and Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10:209-219.
61. Nishino S, Ohtomo K, Numata Y, Sato T, Nakahata N and Kurita M (2012) Divergent effects of lithium and sodium valproate on brain-derived neurotrophic factor (BDNF) production in human astrocytoma cells at therapeutic concentrations. Prog Neuropsychopharmacol Biol Psychiatry 39:17-22.
62. Noble W, Planel E, Zehr C, et al. (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102:6990-6995.
63. Nonaka S, Hough CJ and Chuang DM (1998) Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 95:2642-2647.
64. Omata N, Murata T, Takamatsu S, et al. (2008) Neuroprotective effect of chronic lithium treatment against hypoxia in specific brain regions with upregulation of cAMP response element binding protein and brain-derived neurotrophic factor but not nerve growth factor: comparison with acute lithium treatment. Bipolar Disord 10:360-368.
65. Pålhagen S, Qi H, Mårtensson B, Wålinder J, Granérus AK and Svenningsson P (2010) Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J Neurol 257:524-532.
66. Phiel CJ, Wilson CA, Lee VM and Klein PS (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423:435-439.
67. Post RM (2007) Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 41:979-990.
68. Profenno LA, Jakimovich L, Holt CJ, Porsteinsson A and Tariot PN (2005) A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease. Curr Alzheimer Res 2:553-558.
69. Qing H, He G, Ly PT, et al. (2008) Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 205:2781-2789.
70. Rajkowska G (2002) Cell pathology in bipolar disorder. Bipolar Disord 4:105-116.
71. Rockenstein E, Torrance M, Adame A, et al. (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27:1981-1991.
72. Rybakowski JK and Suwalska A (2010) Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol 13:617-622.
73. Schinder AF and Poo M (2000) The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci 23:639-645.
74. Shaltiel G, Chen G and Manji HK (2007) Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 7:22-26.
75. Shimizu E, Hashimoto K, Okamura N, et al. (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54:70-75.
76. Solomon DA, Keitner GI, Ryan CE and Miller IW (1998) Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder. J Clin Psychopharmacol 18:38-49.
77. Stertz L, Fries GR, Aguiar BW, et al. (2013) Histone deacetylase activity and brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania. Rev Bras Psiquiatr 10:0-0 [Epub ahead of print].
78. Su H, Zhang W, Guo J, Guo A, Yuan Q and Wu W (2009) Lithium enhances the neuronal differentiation of neural progenitor cells in vitro and after transplantation into the avulsed ventral horn of adult rats through the secretion of brain-derived neurotrophic factor. J Neurochem 108:1385-1398.
79. Suwalska A, Sobieska M and Rybakowski JK (2010) Serum brainderived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neuropsychobiology 62:229-234.
80. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G and Popoli M (2006) Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 58:115-134.
81. Tariot PN, Loy R, Ryan JM, Porsteinsson A and Ismail S (2002) Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 54:1567-1577.
82. Tariot PN, Schneider LS, Cummings J, et al. (2011) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 68:853-861.
83. Twiss JL, Chang JH and Schanen NC (2006) Pathophysiological mechanisms for actions of the neurotrophins. Brain Pathol 16:320-332.
84. Vecsey CG, Hawk JD, Lattal KM, et al. (2007) Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB: CBP-dependent transcriptional activation. J Neurosci 27:6128-6140.
85. Vecsler M, Simon AJ, Amariglio N, Rechavi G and Gak E (2010) MeCP2 deficiency downregulates specific nuclear proteins that could be partially recovered by valproic acid in vitro. Epigenetics 5:61-67.
86. Wang ZF, Fessler EB and Chuang DM (2011) Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacol Sin 32:1433-1445.
87. Wilot LC, Bernardi A, Frozza RL, et al. (2007) Lithium and valproate protect hippocampal slices against ATP-induced cell death. Neurochem Res 32:1539-1546.
88. Yasuda S, Liang MH, Marinova Z, Yahyavi A and Chuang DM (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14:51-59.
89. Yu F, Wang Z, Tanaka M, et al. (2013) Posttrauma cotreatment with lithium and valproate: reduction of lesion volume, attenuation of bloodbrain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury. J Neurosurg 119:766-773.
90. Yucel K, Taylor VH, McKinnon MC, et al. (2008) Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment. Neuropsychopharmacology 33:361-367.
91. Zarate CA, Du J, Quiroz J, et al. (2003) Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann NY Acad Sci 1003:273-291.
92. Zhang X, Heng X, Li T, et al. (2011) Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis 24:739-749.
93. Zhao S and Fernald RD (2005) Comprehensive algorithm for quantitative real-time polymerase chain reaction. J Comput Biol 12:1045-1062.